WO2004031413A3 - Method for diagnosing non-small cell lung cancers - Google Patents

Method for diagnosing non-small cell lung cancers Download PDF

Info

Publication number
WO2004031413A3
WO2004031413A3 PCT/JP2003/012072 JP0312072W WO2004031413A3 WO 2004031413 A3 WO2004031413 A3 WO 2004031413A3 JP 0312072 W JP0312072 W JP 0312072W WO 2004031413 A3 WO2004031413 A3 WO 2004031413A3
Authority
WO
WIPO (PCT)
Prior art keywords
small cell
cell lung
lung cancers
lung cancer
diagnosing non
Prior art date
Application number
PCT/JP2003/012072
Other languages
French (fr)
Other versions
WO2004031413A9 (en
WO2004031413A2 (en
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Japan President Univ Tokyo
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Japan President Univ Tokyo, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru filed Critical Oncotherapy Science Inc
Priority to EP03753941A priority Critical patent/EP1551998A2/en
Priority to CA002500151A priority patent/CA2500151A1/en
Priority to JP2004541231A priority patent/JP4425141B2/en
Priority to AU2003272088A priority patent/AU2003272088A1/en
Publication of WO2004031413A2 publication Critical patent/WO2004031413A2/en
Publication of WO2004031413A3 publication Critical patent/WO2004031413A3/en
Priority to US11/090,617 priority patent/US20060024692A1/en
Publication of WO2004031413A9 publication Critical patent/WO2004031413A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Disclosed are methods for detecting non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes whose expression is elevated in non-small cell lung cancer compared to no-cancerous tissues are provided. Also disclosed are methods of identifying compounds for treating and preventing non-small cell lung cancer.
PCT/JP2003/012072 2002-09-30 2003-09-22 Method for diagnosing non-small cell lung cancers WO2004031413A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03753941A EP1551998A2 (en) 2002-09-30 2003-09-22 Method for diagnosing non-small cell lung cancers
CA002500151A CA2500151A1 (en) 2002-09-30 2003-09-22 Ttk protein kinase gene for diagnosing and treating non-small cell lung cancers
JP2004541231A JP4425141B2 (en) 2002-09-30 2003-09-22 Methods for diagnosis of non-small cell lung cancer
AU2003272088A AU2003272088A1 (en) 2002-09-30 2003-09-22 Method for diagnosing non-small cell lung cancers
US11/090,617 US20060024692A1 (en) 2002-09-30 2005-03-24 Method for diagnosing non-small cell lung cancers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41467302P 2002-09-30 2002-09-30
US60/414,673 2002-09-30
US45137403P 2003-02-28 2003-02-28
US60/451,374 2003-02-28
US46610003P 2003-04-28 2003-04-28
US60/466,100 2003-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/090,617 Continuation-In-Part US20060024692A1 (en) 2002-09-30 2005-03-24 Method for diagnosing non-small cell lung cancers

Publications (3)

Publication Number Publication Date
WO2004031413A2 WO2004031413A2 (en) 2004-04-15
WO2004031413A3 true WO2004031413A3 (en) 2005-02-24
WO2004031413A9 WO2004031413A9 (en) 2005-08-04

Family

ID=32074369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/012072 WO2004031413A2 (en) 2002-09-30 2003-09-22 Method for diagnosing non-small cell lung cancers

Country Status (8)

Country Link
EP (30) EP2278028A1 (en)
JP (4) JP4425141B2 (en)
KR (2) KR101075158B1 (en)
AT (1) ATE541053T1 (en)
AU (1) AU2003272088A1 (en)
CA (1) CA2500151A1 (en)
TW (1) TW200413725A (en)
WO (1) WO2004031413A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300469A (en) * 1992-12-08 1994-04-05 Engelhard Corporation Composition for passivating vanadium in catalytic cracking and preparation thereof
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp Brain endothelial cell expression patterns
WO2004063331A2 (en) * 2003-01-03 2004-07-29 Gencia Corporation SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2007530921A (en) * 2004-03-24 2007-11-01 オンコセラピー・サイエンス株式会社 ADAM8 as a tumor marker and therapeutic target for non-small cell lung cancer
EP2336778A1 (en) * 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
JP5028601B2 (en) * 2004-08-10 2012-09-19 オンコセラピー・サイエンス株式会社 Breast cancer-related genes and polypeptides
JP4874234B2 (en) * 2004-08-10 2012-02-15 オンコセラピー・サイエンス株式会社 Non-small cell lung cancer-related gene ANLN and its interaction with RhoA
ATE479778T1 (en) 2004-09-24 2010-09-15 Oncotherapy Science Inc METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CARCINOMAS VIA THE TRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
EP1812796B1 (en) 2004-10-19 2009-12-09 Oncotherapy Science, Inc. Pkp3 oncogene as a prognostic indicator for lung adenocarcinoma
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2007053161A2 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
ES2459466T3 (en) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
CA2599875A1 (en) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
DE102005052384B4 (en) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for the detection, labeling and treatment of epithelial lung tumor cells and means for carrying out the method
KR100759288B1 (en) * 2005-11-14 2007-09-17 가톨릭대학교 산학협력단 Diagnostic Methods of Lung Cancer and Its Subtypes by CGH
CN101415440A (en) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 Method for treating lung cancer
WO2007123247A1 (en) * 2006-04-20 2007-11-01 Oncotherapy Science, Inc. NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER
CA2655851A1 (en) * 2006-08-01 2008-02-07 F. Hoffmann-La Roche Ag Use of nnmt as a marker for lung cancer
JP2010501162A (en) * 2006-08-18 2010-01-21 オンコセラピー・サイエンス株式会社 IMP-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
WO2008020653A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Use of holliday junction-recognizing protein related to cancer
EP2423333A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
US20080145313A1 (en) * 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
CN102850435B (en) 2006-10-17 2016-02-17 肿瘤疗法科学股份有限公司 For expressing the peptide vaccine of the cancer of MPHOSPH1 or DEPDC1 polypeptide
EP2468887A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
KR100846354B1 (en) * 2007-03-21 2008-07-15 (주) 프로탄바이오 Diagnostic biomarker for lung adenocarcinoma isolated from serum glycoproteins
JP2010523081A (en) * 2007-03-30 2010-07-15 オンコセラピー・サイエンス株式会社 Screening method targeting CDCA8-AURKB complex and method for treating NSCLC
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
EP2185732A1 (en) * 2007-07-30 2010-05-19 Oncotherapy Science, Inc. Cancer associated gene ly6k
US8569244B2 (en) 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
RU2486195C2 (en) 2007-08-20 2013-06-27 Онкотерапи Сайенс, Инк. Cdca1 peptide and pharmaceutical drug containing it
ES2632123T3 (en) 2007-08-20 2017-09-11 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
JP5676107B2 (en) 2007-11-14 2015-02-25 中外製薬株式会社 Diagnosis and treatment of cancer using anti-GPR49 antibody
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
CN102137929B (en) 2008-06-30 2013-07-10 肿瘤疗法科学股份有限公司 Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
TWI466680B (en) 2008-08-01 2015-01-01 Oncotherapy Science Inc Melk epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (en) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
WO2010023856A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
US20120022131A1 (en) * 2008-08-27 2012-01-26 Oncotherapy Science Inc. Breast cancer related gene rqcd1
RU2011111411A (en) * 2008-08-28 2012-10-10 Онкотерапи Сайенс, Инк. (Jp) OIP5 AS TARGET GENE FOR THERAPY AND DIAGNOSTICS OF CANCER
KR101064561B1 (en) * 2008-09-24 2011-09-14 고려대학교 산학협력단 Bio marker for predicting early-relapse after operation for lung adenocarcinoma
EP2373794A4 (en) * 2008-12-12 2012-09-05 Oncotherapy Science Inc Nectin-4 for target genes of cancer therapy and diagnosis
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
ES2703714T3 (en) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Methods of identification, evaluation, prevention and therapy of pulmonary diseases and kits thereof, including the identification, evaluation, prevention and therapy of diseases on the basis of gender
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
HUE037593T2 (en) * 2009-09-03 2018-09-28 Toray Industries Immunity inducer
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
TWI485245B (en) 2010-01-25 2015-05-21 Oncotherapy Science Inc Modified melk peptides and vaccines containing the same
EP2545171B1 (en) 2010-03-11 2017-12-20 OncoTherapy Science, Inc. Hjurp peptides and vaccines including the same
WO2011129427A1 (en) * 2010-04-16 2011-10-20 第一三共株式会社 Diagnostic agent and therapeutic agent for cancer
SG187633A1 (en) 2010-07-30 2013-03-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
EP2611930A1 (en) * 2010-09-02 2013-07-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis of cancer
AU2012249288C1 (en) * 2011-04-29 2017-12-21 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2012153492A1 (en) * 2011-05-06 2012-11-15 Oncotherapy Science, Inc. Nptx2 as tumor marker and therapeutic target for cancer
WO2012157239A1 (en) * 2011-05-16 2012-11-22 Oncotherapy Science, Inc. Chodl as tumor marker and therapeutic target for cancer
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
CN103987861A (en) 2011-10-14 2014-08-13 加州大学评议会 Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
BR112014014877B1 (en) 2012-01-19 2020-09-08 Oncotherapy Science, Inc. 1,5-NAFTHYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME, ITS USE, PHARMACEUTICAL COMPOSITION, MELK INHIBITOR, MELK EXPRESSION AGENT, ANTITUMORAL AGENT AND THERAPEUTIC AND / OR PREVENTIVE AGENT FOR A SUPEREX PRESSURE DISEASE. , CONTAINING THE SAME
KR101308924B1 (en) * 2012-02-21 2013-09-23 차의과학대학교 산학협력단 NOVEL miRNA hc-smR-S2-5 AND USE THEREOF
JP6159996B2 (en) 2012-03-09 2017-07-12 株式会社富士薬品 Pharmaceutical composition comprising a peptide
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
JP6255594B2 (en) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 LY6K epitope peptide of Th1 cell and vaccine containing the same
US9687538B2 (en) 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
GB201213229D0 (en) * 2012-07-25 2012-09-05 Isis Innovation Assay
TWI658049B (en) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2 peptides and vaccines containing the same
KR101447901B1 (en) 2013-04-16 2014-10-16 한양대학교 산학협력단 Adipocyte targeted non-viral gene delivery system
TWI627182B (en) 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 Imp-3 epitope peptides for th1 cells and vaccines containing the same
EP3149209B1 (en) 2014-05-30 2021-02-17 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
KR20220165831A (en) 2014-08-04 2022-12-15 온코세라피 사이언스 가부시키가이샤 Urlc10-derived peptide and vaccine containing same
CN111925414A (en) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 KOC 1-derived peptides and vaccines containing the same
WO2016121715A1 (en) * 2015-01-26 2016-08-04 国立大学法人名古屋大学 Method for providing information for evaluating prognosis of lung cancer patient, method for predicting prognosis of lung cancer patient, internal standard, antibody, device for predicting prognosis of lung cancer patient, program for prognosis prediction device, and recording medium
CN107849613A (en) * 2015-04-14 2018-03-27 基因中心治疗公司 Method for lung cancer parting
JP6895175B2 (en) * 2015-09-09 2021-06-30 テオリアサイエンス株式会社 Exosome secretion inhibitor
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
JP6857909B2 (en) 2015-10-08 2021-04-14 オンコセラピー・サイエンス株式会社 MPHOSPH1-derived peptide and vaccine containing it
CN109790583B (en) 2016-05-17 2023-08-25 基因中心治疗公司 Methods for typing lung adenocarcinoma subtypes
JP7241352B2 (en) 2016-05-17 2023-03-17 ジーンセントリック セラピューティクス， インコーポレイテッド Methods for subtyping lung squamous cell carcinoma
BR112019003408A2 (en) 2016-08-31 2019-06-25 Oncotherapy Science Inc monoclonal antibody against melk and its use
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
EP3607089A4 (en) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC Plasma based protein profiling for early stage lung cancer prognosis
CN112673475A (en) 2019-07-31 2021-04-16 京东方科技集团股份有限公司 Display substrate, preparation method thereof, display panel and display device
KR20220157009A (en) 2021-05-20 2022-11-29 한국식품연구원 Method for early diagnosing and predicting the risk of lung cancer using oral microbiome or composition thereof
CN113925877B (en) * 2021-10-28 2022-06-07 青岛西凯生物技术有限公司 Application of gene-enhanced immune cells in lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072775A2 (en) * 2000-03-29 2001-10-04 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114005D0 (en) 1991-06-28 1991-08-14 Automotive Prod Plc A clutch control system
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5403494A (en) 1993-07-15 1995-04-04 The Lawrence Paper Company Method of recovery of single color printing ink wastes
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7122373B1 (en) * 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
EP1053319A2 (en) * 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
PT1200590E (en) * 1999-08-12 2009-03-24 Agensys Inc C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1268528A2 (en) * 2000-03-28 2003-01-02 Chiron Corporation Human genes and expression products
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
CA2415544A1 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
JP4429604B2 (en) * 2001-02-21 2010-03-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド TTK in diagnosis and TTK as a therapeutic target in cancer
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005527180A (en) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド Lung cancer diagnosis method, composition of lung cancer modifier and screening method
EP2336778A1 (en) * 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
ES2459466T3 (en) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
EP2423333A1 (en) * 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
KR20100075857A (en) * 2007-08-24 2010-07-05 온코세라피 사이언스 가부시키가이샤 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072775A2 (en) * 2000-03-29 2001-10-04 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROSELL RAFAEL ET AL: "Translational oncogenomics: Toward rational therapeutic decision-making", CURRENT OPINION IN ONCOLOGY, vol. 14, no. 2, March 2002 (2002-03-01), pages 171 - 179, XP008027342, ISSN: 1040-8746 *
WANG T ET AL: "IDENTIFICATION OF GENES DIFFERENTIALLY OVER-EXPRESSED IN LUNG SQUAMOUS CELL CARCINOMA USING COMBINATION OF CDNA SUBTRACTION AND MICROARRAY ANALYSIS", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, no. 12, 16 March 2000 (2000-03-16), pages 1519 - 1528, XP000951444, ISSN: 0950-9232 *
WIGLE DENNIS A ET AL: "Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.", CANCER RESEARCH. UNITED STATES 1 JUN 2002, vol. 62, no. 11, 1 June 2002 (2002-06-01), pages 3005 - 3008, XP002271233, ISSN: 0008-5472 *
YANIV KARINA ET AL: "The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis", GENE (AMSTERDAM), vol. 287, no. 1-2, 3 April 2002 (2002-04-03), pages 49 - 54, XP002271204, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
EP2264457A1 (en) 2010-12-22
EP2270501A2 (en) 2011-01-05
EP2270211A2 (en) 2011-01-05
EP2270212A2 (en) 2011-01-05
EP2270218A2 (en) 2011-01-05
KR101075158B1 (en) 2011-10-19
EP2270224A3 (en) 2011-10-05
WO2004031413A9 (en) 2005-08-04
EP2270219A3 (en) 2011-07-27
EP2270216A2 (en) 2011-01-05
EP2264186A1 (en) 2010-12-22
AU2003272088A1 (en) 2004-04-23
EP2270222A2 (en) 2011-01-05
WO2004031413A2 (en) 2004-04-15
EP2278028A1 (en) 2011-01-26
EP1743947A3 (en) 2007-05-23
KR20050074468A (en) 2005-07-18
JP4425141B2 (en) 2010-03-03
EP2270221A3 (en) 2011-09-28
EP1743947B1 (en) 2012-01-11
EP2270214A2 (en) 2011-01-05
EP2270224A2 (en) 2011-01-05
TW200413725A (en) 2004-08-01
EP2270217A3 (en) 2011-07-27
EP2270221A2 (en) 2011-01-05
EP2264187A1 (en) 2010-12-22
JP2006500949A (en) 2006-01-12
EP2270211A3 (en) 2011-06-22
EP2270213A2 (en) 2011-01-05
EP2270219A2 (en) 2011-01-05
EP2270213A3 (en) 2011-06-29
EP2270503A3 (en) 2011-01-19
EP2270498A2 (en) 2011-01-05
CA2500151A1 (en) 2004-04-15
EP2270215A2 (en) 2011-01-05
EP2270212A3 (en) 2011-06-29
EP2270498A3 (en) 2011-02-02
EP2270499A1 (en) 2011-01-05
EP2270210A2 (en) 2011-01-05
EP2270215A3 (en) 2011-07-20
EP1743947A2 (en) 2007-01-17
JP4921522B2 (en) 2012-04-25
EP2270216A3 (en) 2011-07-20
EP2270225A3 (en) 2011-10-05
EP2270220A2 (en) 2011-01-05
EP2270217A2 (en) 2011-01-05
AU2003272088A8 (en) 2004-04-23
EP2270210A3 (en) 2011-06-22
EP2264190A1 (en) 2010-12-22
JP2010042016A (en) 2010-02-25
EP2270502A2 (en) 2011-01-05
EP2270220A3 (en) 2011-09-28
JP2009240313A (en) 2009-10-22
EP2270501A3 (en) 2011-01-19
EP2264185A1 (en) 2010-12-22
EP1551998A2 (en) 2005-07-13
ATE541053T1 (en) 2012-01-15
KR20110020953A (en) 2011-03-03
EP2270502A3 (en) 2011-01-26
EP2270214A3 (en) 2011-07-20
EP2270223A2 (en) 2011-01-05
EP2270500A1 (en) 2011-01-05
EP2270225A2 (en) 2011-01-05
JP2012125247A (en) 2012-07-05
EP2270503A2 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
WO2004031413A3 (en) Method for diagnosing non-small cell lung cancers
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
WO2006039405A3 (en) Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods and kits thereof
WO2004056874A3 (en) Neuropilin-1 inhibitors
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001094629A3 (en) Cancer gene determination and therapeutic screening using signature gene sets
WO2005024603A3 (en) Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2005017493A3 (en) Biomarkers in cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003302732A1 (en) Method for identifying risk of breast cancer and treatments thereof
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2007027421A3 (en) Method for diagnosing non-small cell lung carcinoma
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2003228984A1 (en) Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006063285A3 (en) Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
EP1832876A3 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
UA36390A (en) Method for differential diagnostics of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2500151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11090617

Country of ref document: US

Ref document number: 2004541231

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057005561

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003753941

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038255065

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003753941

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057005561

Country of ref document: KR

COP Corrected version of pamphlet

Free format text: PAGE 8/50, DRAWINGS, ADDED

WWP Wipo information: published in national office

Ref document number: 11090617

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003753941

Country of ref document: EP